Cassava Sciences (SAVA) Upgraded to Strong Buy by sfbanc
The Californer/10206797

WEST HOLLYWOOD, Calif. - Californer -- Simufilam is a leading candidate to become the first effective treatment for Alzheimer's Disease. In an analysis by sfbanc financial, Cassava Sciences, Inc. (SAVA) was upgraded as a Strong Buy, from 8/10 to 9.5/10.

The drug in development purportedly works by retiring the proper conformation of filamin A, a molecule involved in the cascade of Alzheimer's disease. Open-label results are showing effectiveness in 84% of subjects treated. These promising results, along with recent insider buying, has led the sfbanc community to upgrade the stock.

More on The Californer

• Nextvisit Co-Founder Ryan Yannelli Identifies Six Critical Factors for Behavioral Health Providers Evaluating AI Scribes in 2026
• BrassTranscripts Introduces Flat-Rate Pricing with Up to 67% Savings on Long-Form Audio
• Long Beach: City Achieves Housing Milestone: Over 5,000 New Homes Approved
• CredHub and Real Property Management Join Forces to Empower Franchise Owners with Rental Payment Credit Reporting Solutions
• Dodd, Mead & Company Revived Under Current Trademark Ownership

Additional results from the open label trial are expected by the end of this year. Call volume shows optimism for the results of the Cognitive Maintenance Study (CMS) in late 2023. This trial will include 100 subjects randomized to switch from active drug to placebo. Simufilam is currently in two randomized placebo-controlled Phase 3 trials.

sfbanc is a financial community that provides analysis and discussion of available public information in the finance sector. https://sfbanc.com